Biosimilars/General

South Korea’s Celltrion to sell directly to Australia

Biosimilars/General | Posted 09/08/2019

In a successful month for Celltrion, the company announces plans to directly sell its anticancer biosimilars in Australia and begins a clinical trial for allergy treatment CT-P39.

NHS England updates its ‘What is a Biosimilar Medicine?’

Biosimilars/General | Posted 02/08/2019

The National Health Service (NHS) England announced that it had updated its ‘What is a Biosimilar Medicine?’ document in June 2019.

South Korea increases investment in biologicals

Biosimilars/General | Posted 26/07/2019

Investment in the biotech sector is ramping up in South Korea, with increased state-led support and private sector pledges.

Eli Lilly launches lower-priced insulin lispro

Biosimilars/General | Posted 14/06/2019

Eli Lilly announced on 22 May 2019 that it had launched the lower-priced authorized biosimilar version of its diabetes treatment Humalog (insulin lispro) in the US.

UnitedHealthcare to prefer brand-name pegfilgrastim

Biosimilars/General | Posted 14/06/2019

US health insurance provider UnitedHealthcare has announced that it will prefer use of brand-name pegfilgrastim over the biosimilar versions.

Irish hospitals to get incentives to switch patients to biosimilars

Biosimilars/General | Posted 07/06/2019

Hospitals in Ireland are being offered a Euros 500 incentive for every patient they switch off two expensive biologicals to cheaper biosimilars.

Settlement for Udenyca and win for Zarxio

Biosimilars/General | Posted 31/05/2019

Amgen has made a settlement with respect to pegfilgrastim biosimilar Udenyca, but has lost its appeal against filgrastim biosimilar Zarxio.

Biocon/Mylan gain global rights to adalimumab biosimilar Hulio

Biosimilars/General | Posted 31/05/2019

India-based biologicals specialist Biocon and US-based partner Mylan announced on 7 May 2019 that they have gained the global rights to the adalimumab biosimilar Hulio.

Recommendations published by Canadian breast cancer advocacy group

Biosimilars/General | Posted 24/05/2019

In April 2019, an advocacy group for patients with breast cancer in Canada – the Canadian Breast Cancer Network (CBCN) - published recommendations related to use of biosimilars in a white paper, entitled ‘Breast Cancer & Biosimilars Recommendations on Use, Implementation and Patient Communications’. These recommendations were informed by insights collected from virtual roundtable discussions with patients and medical oncologists. 

Canadian organizations collaborate to improve biosimilar adoption in cancer and inflammatory rheumatic and bowel disease

Biosimilars/General | Posted 17/05/2019

With a number of biosimilars expected to launch in Canada in 2019 and beyond, Canadian organizations are collaborating to improve biosimilar adoption. Canada lags behind the European Union in terms of approval and uptake of biosimilars [1].